[{"indications": "Indications\u00a0major depression", "name": "AGOMELATINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.3 Antidepressant drugs", "4.3.4 Other antidepressant drugs", "AGOMELATINE"], "cautions": "Cautions\u00a0elderly; mania or hypomania; concomitant\r\nuse of drugs associated with hepatic injury; excessive alcohol consumption; obesity; non-alcoholic\r\nfatty liver disease; monitor liver function before treatment\r\nand after 6, 12 and 24 weeks of treatment, then as appropriate\r\n(discontinue if serum transaminases exceed 3 times the\r\nupper limit of reference range); interactions: Appendix 1 (agomelatine)", "side-effects": "Side-effects\u00a0nausea, diarrhoea, constipation, abdominal pain,\r\nincreased serum transaminases (see Cautions); headache, dizziness,\r\ndrowsiness, agitation, sleep disturbances, fatigue, anxiety; back\r\npain; sweating; less commonly paraesthesia, blurred\r\nvision, and eczema; rarely hepatitis and rash; suicidal\r\nbehaviour (see Suicidal Behaviour and Antidepressant\r\nTherapy)\r\nand pruritus also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/202510.htm", "doses": ["adult over 18 years, 25\u00a0mg\r\nat bedtime, increased if necessary after 2 weeks to 50\u00a0mg at bedtime "], "pregnancy": "Pregnancy\u00a0caution"}]